SLC5A2 and cardiovascular disorder: They recommend the preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium−glucose cotransporter 2 (SGLT-2) inhibitors that have proven renal and cardiovascular benefits for patients with established cardiovascular disease or those at high risk for cardiovascular disease if there are no contraindications for their use (5–8).